1 August 2004 in Cancer Research
CpG oligodeoxynucleotides (ODNs) are synthetic DNA sequences containing unmethylated cytosine-guanine motifs with potent immunomodulatory effects. Via Toll-like receptor 9 agonism of dendritic cells and B cells, CpG ODNs induce cytokines, activate natural killer cells, and elicit vigorous T-cell responses that lead to significant antitumor effects, including improved efficacy of chemotherapeutic agents. On the basis of these properties of CpG ODNs, we tested whether they also could enhance tumor response to radiotherapy. Using an immunogenic mouse tumor, designated FSa, the response to radiotherapy was assayed by tumor growth delay and tumor cure rate (TCD50, radiation dose yielding 50% tumor cure rate). Treatments were initiated when established tumors were either 6 or 8 mm in diameter. CpG ODN as a single agent given s.c. peritumorally had little effect on tumor growth; however, it dramatically enhanced tumor growth delay in response to single-dose radiation by a factor of 2.58–2.65. CpG ODN also dramatically improved tumor radiocurability, reducing the TCD50 by a factor of 1.93, from 39.6 (36.1–43.1) Gy to 20.5 (14.3–25.7) Gy. The CpG ODN-induced enhancement of tumor radioresponse was diminished in tumor-bearing mice immunocompromised by sublethal whole-body radiation. Tumors treated with CpG ODN and radiation showed histologic changes characterized by increased necrosis, heavy infiltration by host inflammatory cells (lymphocytes and granulocytes), and reduced tumor cell density. These results show that CpG ODNs are potent enhancers of tumor radioresponse and as such have potential to improve clinical radiotherapy.
14 May 2018 in Journal of Neurological Surgery Part B: Skull Base
Objectives This article aims to clarify the long-term outcomes of patients with squamous cell carcinoma of the temporal bone who underwent concomitant chemoradiotherapy (CCRT). Design and Setting The study design was a retrospective chart review. Patients and Methods From December 2001 to June 2014, 23 patients with cancer of the temporal bone who were treated by CCRT at the Tohoku University Hospital and the Iwate Medical University Hospital were enrolled in this study. For advanced cancer of the temporal bone, a modified docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen was used for CCRT. The long-term outcomes, including prognoses and late complications, were analyzed after CCRT of patients with cancers of the temporal bone. Results The main long-term complications were stenosis of the external auditory canal and conductive hearing loss. No harmful late complications were observed in these patients. Disease-specific survival rates were 84.9% for all patients, 100% for patients of stage I, II, and III (n = 10), and 75.5% for patients of stage IV (n = 13) at 5 years. Conclusions Our study showed that CCRT is an effective treatment choice for squamous cell carcinoma of the temporal bone. Furthermore, CCRT using the TPF regimen is a safe and effective initial treatment for patients with advanced cancers of the temporal bone.
4 May 2021 in Clinical Case Reports
This case report highlights the need for clinicians to monitor patients with rhabdomyosarcoma for pancreatic metastasis to ensure that proper treatment is quickly provided, thereby improving outcomes.
1 May 2024 in Review of Scientific Instruments
This study was aimed at developing a dose-rate dosimeter to measure the instantaneous dose rate of a commercially available medical linear accelerator. A dose-rate dosimeter composed of a silicon photodiode (Si-PD), a complementary metal-oxide semiconductor single operational amplifier, a resistor of 20 MΩ, a capacitor of 100 pF, and a mini-substrate measuring 16 × 16 mm2 was evaluated. Voltage outputs from the proposed dosimeter were measured using an analog-to-digital converter on a microcomputer. A custom-made x-ray tube generator at an energy of 120 kV with a tube current ranging from 0.1 to 2.0 mA was used for the dose-rate calibration. Dose-rate calibration was performed 83.3 mm from an x-ray source using a commercially available semiconductor dosimeter. The developed Si-PD dosimeter could measure up to 0.6 Gy/s at a distance of 19.3 mm from the x-ray source. Measurements were also performed using a medical linear accelerator in a 10 MV flattening filter-free mode at depths of 0, 25, 50, and 100 mm with an irradiation field of 100 × 100 mm2 at a constant distance of 1000 mm from the source to the dosimeter. A peak voltage variation corresponding to the instantaneous dose rate was observed using a sampling period of 1.0 ms, and the peak voltages decreased with the depth. The detected pulse numbers were 512, 484, 491, and 511 at depths of 0, 25, 50, and 100 mm, respectively.